Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747038 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL1747373 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL1746292 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL1746122 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL1746452 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL1746076 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL1746085 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL14312713 | 1.00 | CES2 (0.49) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL28115646 | 0.86 | CES2 (0.47) | CES2CES1LMNAEPHX2PAM | |
| SCHEMBL6376734 | 0.85 | CES2 (0.44) | CES2CES1EPHX2PAMDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948196-B1 | USE OF TETRAORGANOSILICON COMPOUNDS | SALAMA ZOSER B (DE) | 2012-12-26 | — | — | EP | claimed |
| EP-2563337-B1 | CARRIER AND TARGETING SYSTEM COMPRISING A SIOSOMAL COMPOSITION FOR INTRACELLULAR DELIVERY AND TARGETING OF ACTIVE SUBSTANCE | SALAMA ZOSER B (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2563337-B1 | CARRIER AND TARGETING SYSTEM COMPRISING A SIOSOMAL COMPOSITION FOR INTRACELLULAR DELIVERY AND TARGETING OF ACTIVE SUBSTANCE | SALAMA ZOSER B (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-1948196-B1 | USE OF TETRAORGANOSILICON COMPOUNDS | SALAMA ZOSER B (DE) | 2012-12-26 | — | — | EP | disclosed |
| EP-2384743-A1 | Siosomal formulation for intracellular delivery and targeting of therapeutic agents | Salama, Zoser B. (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20100247578-A1 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF | SALAMA ZOSER B | 2010-09-30 | — | — | US | disclosed |
| EP-0483465-B1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | SALAMA ZOSER BOULIS DR (DE) | 1995-08-02 | — | — | EP | disclosed |
| EP-0483465-A1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | Salama, Zoser Boulis, Dr. (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247578-A1 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF | EXOSC5, EXOSC9, SSB | CES2 3398/4885CES1 3694/4885LMNA 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.